Hexaxim

Per 0.5 mL Diphtheria toxoid not <20 IU, tetanus toxoid not <40 IU; Bordetella pertussis antigens: Pertussis toxoid 25 mcg, filamentous haemagglutinin 25 mcg; inactivated poliovirus: Type 1 (Mahoney) 40 D-antigen units, type 2 (MEF-1) 8 D-antigen units, type 3 (Saukett) 32 D-antigen units; HBsAg 10 mcg, HIB polysaccharide 12 mcg (polyribosylribitol phosphate) conjugated to tetanus protein 22-36 mcg

Primary & booster vaccination of infants & toddlers from 6 wk-24 mth against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis & invasive diseases caused by HIB.

IM Primary vaccination 3 doses of 0.5 mL w/ at least 4 wk interval & as per schedules 6, 10, 14 wk; 2, 3, 4 mth; 3, 4, 5 mth; 2, 4, 6 mth. Booster vaccination 2nd yr of life at least 6 mth after last priming dose.

Hypersensitivity to vaccine after previous inj, trace residuals (eg, glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B) or any pertussis vaccine. Encephalopathy of unknown aetiology occurring w/in 7 days following prior vaccination. Not to be used in patients w/ uncontrolled neurologic disorder or epilepsy.

Not to be inj intravascularly, intradermally or SC. Not for prevention of diseases caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, HBV, poliovirus or HIB nor for protection against infection by other agents eg, HAV, HCV, hepatitis E virus or other liver pathogens; other types of H influenzae or meningitis of other origins. Postpone immunization in patients w/ moderate to severe acute febrile illness or infection. Temp ≥40°C, collapse or shock-like state, persistent inconsolable crying lasting ≥3 hr w/in 48 hr of vaccination; convulsions w/ or w/o fever occurring w/in 3 days of vaccination. History of febrile convulsions or Sudden Infant Death Syndrome; Guillain-Barre syndrome or brachial neuritis; thrombocytopenia or bleeding disorder; syncope; immunosuppressive treatment or immunodeficiency; impaired hepatitis B response; phenylketonuria. Interference w/ lab urine test. Chronic renal failure. Not intended for women of childbearing age. Pregnancy & lactation. Childn >24 mth. Resp monitoring for 48-72 hr in very premature infants (≤28 wk of gestation) & w/ previous history of resp immaturity.

Anorexia; crying, somnolence; vomiting; inj site pain, erythema & swelling, irritability, pyrexia (≥38°C). Abnormal/prolonged crying; diarrhoea; inj site induration.

Not to be mixed w/ any other vaccines or parenterally-administered medicinal products.

Vaccines, Antisera & Immunologicals

J07CA09 - diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B ; Belongs to the class of combined bacterial and viral vaccines.

B